Calculated Values for Low-Density LipoproteinCholesterol in the Assessment of Lipid Abnormalities and Coronary Disease Risk

Size: px
Start display at page:

Download "Calculated Values for Low-Density LipoproteinCholesterol in the Assessment of Lipid Abnormalities and Coronary Disease Risk"

Transcription

1 CLIN. CHEM. /1, - (199) Calculated Values for Low-Density LipoproteinCholesterol in the Assessment of Lipid Abnormalities and Coronary Disease Risk Judith R. McNamara, Jeffrey S. Cohn, Peter W. F. WIlson,and ErnstJ. Schaefer Low-density Ilpoprotein (LOL) cholesterol concentrations are most commonly estimated by the formula LDL cholesterol = total cholesterol - [triglycerides (TG)/ + high-density lipoprotein cholesterol], although alternative factors such as TG/ have also been used. Using standardized, automated, enzymatic lipid assays, we analyzed 797 plasma samples from normal and dyslipidemic adults, to compare LDL cholesterol concentrations obtained after ultracentrifugation with those calculated by several such methods (i.e., TG/-TG/). For TG concentrations O. g/l, TG/ agreed best with the direct assay; for TG of.1-. g/l, TG/. was best; and for TG of.1-. g/l, TG/ was best. Differences in estimated values were generally small, however. At TG >. g/l, none of the factors tested allowed a reliable estimate of LDL cholesterol. When TG were. gil, % of estimated LDL cholesterol values were properly classified according to National Cholesterol Education Program cutpoints when the factor TG/ was used. We conclude that a convenient direct method for measuring LDL cholesterol is needed but, until one is available, use of the factor TGI will assure that most individuals with TG. g/l, as measured in a standardized laboratory, can be reasonably well classified for risk of coronary artery disease. AdditIonal Keyphraees: estimation compared with direct assay (post-u!tracentrifugation). screening heart disease risk factors Several studies have shown a significantly increased risk of coronary artery disease (CAD) with increasing concentrations of cholesterol in serum or plasma. This increase in risk is primarily due to increased low-density lipoprotein (LDL) cholesterol (1-). Moreover, prospectivestudieshave shown that when high LDL cholesterol concentrations are decreased by use of diet and drugs, the subsequent incidence of CAD is diminished (-). Therefore, the National Cholesterol Education Program s (NCEP) Adult Treatment Panel has recommended the screening of adults for cholesterol abnormalities to assess each individual s CAD risk (9). When the total cholesterol concentration exceeds. Lipid Metabolism Laboratory, USDA Human Nutrition Research Center on Aging at Tufts University, 1 Washington St., Boston, MA 111. F thngham Heart Study, National Heart, Blood and Lung Institute, Framingham, MA. Address correspondence to this author. Presented in part at ClinChem-, Springfield, MA, November, 19. Nonstandard abbreviations: VLDL, LDL, and HDL, very-low, low- and high-density lipoproteins; TG, triglycerides; CAD, coronary artery disease; HNRC, USDA Human Nutrition Research Center on Aging at Tufts University; FHS, Framingham Heart Study; NCEP, National Cholesterol Education Program; CDC, Centers for Disease Control; and NHLBI, National Heart, Lung, and Blood Institute, NIH. Received June, 199; accepted August 1, 199. g/l, or when it exceeds. g/l and two or more other CAD risk factors are present, NCEP has recommended further lipoprotein testing to determine the concentration of LDL cholesterol. LDL cholesterol concentration then becomes the basis for definitive dietary and drug treatment. Currently, LDL cholesterol concentration cannot be determined directly from serum or plasma without use of cumbersome ultracentrifugation procedures. The reference procedure for measuring LDL cholesterol is based on measurement of cholesterol in the density fraction >1. kgfl after ultracentrifugation (1). Because ultracentrifugation is not available in most clinical laboratories, assessment of LDL cholesterol usually is based on indirect calculations made from total cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides (TG), which are usually unblanked for free glycerol (11, 1). The validity of calculated LDL cholesterol values therefore does not depend on the accuracy of one direct assay, but rather on the accuracy of three other assays, plus a mathematical calculation factor that estimates the amount of cholesterol in very-low-density lipoproteins (VLDL). We wanted to test the effect of using calculation factors on the categorizationof subjects in a lipid clinic and in a normal population, with respect to NCEP guidelines. Using assays standardized by the Centers for Disease Control- National Heart, Lung, and Blood Institute (CDC-NHLBI) (), we compared LDL cholesterol values obtained after ultracentrifugation (1) with those obtained by estimation. We tested several estimation factors: (a) the formula of Friedewald et al. (11), (b) the method of DeLong et al. (1), and (c) other similar factors to see which of these might give more nearly accurate estimations of LDL cholesterol at various concentrations of TG. Materials and Methods Study Populations The two independent populations of adults, all older than years,that were used for the present analysis had blood sampled after a 1- to 1-h overnight fast. The first population of 19 individuals consisted of two major subgroups: dyslipidemic patients referred to the Lipid Clinic at New England Medical Center, Boston, MA, and 7 research study subjects from the USDA Human Nutrition Research Center on Aging at Tufts University (HNRC). Plasma lipids and lipoproteins for both subgroups were determined by the HNRC Lipid Metabolism Laboratory. The second population consisted of adults who participated in Cycle of the offspring follow-up of the Framingham Heart Study (FHS), Framinghain, MA, for whom lipid and lipoprotein analyses were performed in the FHS laboratory. The FHS population represented an epidemiological cross-section of a normally distributedpopulation (mean ± SD: TG = 1. ± 1.1 g/l, LDL cholesterol = 1. ±. g/l). The HNRC population, however, consisted of two CLINICAL CHEMISTRY, Vol., No. 1, 199

2 diverse subgroups: the Lipid Clinic patients had a high predominance of lipid abnormalities (TG =. ±.1 g/l, LDL cholesterol = 1. ±. g/l), and the research subjects generally had low-to-normal lipid values (TG =. ±.1 g/l, LDL cholesterol = 1. ±. g/l). The only samples excluded before this data set (n = 797) was compiled were samples drawn from non-fasting individuals, those for which ultracentrifugation was not performed, and those from individuals younger than 1 years. Upoprotein Analysis Blood was drawn into tubes containingedta (1. gil final concentration). Plasma, separated after centrifugation (1 X g, mm, #{17}C), was stored at #{17}C until analysis. For both populations, lipid and lipoprotein analyses were performed by identical methodogy, but in separate laboratory facilities. An aliquot of each sample was subjectedtoultracentrifugation (1 h, x g, #{17}C) at a plasma density of 1. kgfl, with L- ultracentrifuges and.ti rotors (Beckman Instruments, Inc., Palo Alto, CA). After ultracentrifugation, the d <1. fraction was separated from the d >1. fraction by tube slicing (Nuclear Supply & Service Co., Washington, DC). Total cholesterol, TG (unblanked for free glycerol), 1. kg/l infranate cholesterol, and HDL cholesterol concentrations were determined with Abbott Diagnostics ABA- bichromatic analyzers and enzymatic reagents (Abbott s A- GENT ), as previously described (), after precipitation with dextran-mg (1). Lipoprotein cholesterol was calculated by subtraction: total cholesterol - infranate cholesterol = VLDL cholesterol; infranate cholesterol - HDL cholesterol = LDL cholesterol. All HNRC lipid analyses were standardized through the Lipid Standardization Program of the CDC-NHLBI. In addition, LDL cholesterol concentrations were estimated by seven different calculation formulas: (a) the method of Friedewald et al. (11), where total cholesterol - (TG/ + HDL cholesterol) = LDL cholesterol; (b) the method of DeLong et al. (1) with the same formula, except that TG/ is used in place of TG/; and (c-g) by use of the same formula, but with TG/, TGI., TG/., TG/7, or TG/. Statistical Analysis The variables utilized in this study were entered and stored in a VAX 11/7 computer (Digital Equipment Co., Maynard, MA) by using the scientific package RS/i (BBN Research Systems).Mathematical calculations were made with the RB/i software. Paired t-test analyses, performed with the Statistical Analysis Systems (SAS) software (SAS Institute, Cary, NC), were used to compare the significance of the differences between the various calculated estimations of LDL cholesterol and the concentrations determined after ultracentrifligation. Results After ultracentrifugation, the LDL cholesterol concentrations measured in the 19 HNRC samples and the FHS samples were compared with values calculated by each of the estimation methods described above. Because the results for each population, based on unblanked PG concentration and NCEP classification, were very similar, the data were combined. The values shown in Table 1 representthe percentage of samples in each unbianked PG range in which the LDL cholesterol concentration by estimation differed by <1% from the measured concentration. When TG concentrations were s. gil, use of the factor TG/ led to the highest percentage of individuals having values for estimated LDL cholesterol that fell within 1% of measured LDL cholesterol (7%, vs % for TG/. and % for TG/). The factor TG/. gave the closest results, 9%, when PG concentrations were.1-. g/l, vs % for TG/ and % for TG/. However, the differences in the estimated LDL cholesterol values between these three factors were generally small at PG concentrations s.#{17} g/l. Use of the factor TG/ (Friedewald) gave the closest estimations when TG concentrations were.1-. g/l: 7%, vs % for TGI, 9% for TG/., and 7% for TG/.. Above. g/l, no single best estimation factor emerged, but use of the factors TG/ to PG/ generally yieldedthe highest percentages. In the TG range of.1-. g/l, PG/ had the highest percentage of values within 1% of the measured values, but that encompassed only % of the samples with TG values in this range. Additionally, only factors TG/. and TG/ had estimated values that were not significantly different from measured values in the same Table 1. Percent of Samples for Which Estimated LDL Cholesterol Was within 1% of Measured LDL Cholesterol Factor used In estimation TG, g/l n TG/ TG/. TG/ TG/. TG/ TGI7 TGI O *b 79 9* 7*b *b 7 77* b 1 * b 1b * iga b l* 7b >1. b 9*b a Withineach TG range, a indicatestheestimationfactor with the greatestnumber ofsamples with less than 1% difference betweenmeasured andestimated LIX cholesterol concentration. b Estimation factors where the LDL cholesterol concentration was not significantly different(p >.) from the measured concentration by paired ftest analysis. CLINICALCHEMISTRY, Vol., No. 1, 199 7

3 PG range by paired t-test analysis. At concentrations of.1-. gil, PG/ and TG/. gave the closest agreement (%); at concentrations of.1-1. g/l, TG/ was closest at 7%; the g/l range had the best agreement when estimation was calculated with the factor PG/ (1%); and forconcentrations >1. g/l, PG/ had the highest percentage of agreement (9%). Similar results have previously been reported by Kuba and Frantz (1). When the data were analyzed for percent error in the estimated values, similar trends were noted (Table and Figure 1). PG concentrations <. g/l had the lowest percent error when TG/ was used. The percent errorwhen PG were in the range of.1-1. g/l was evenly split between TG/ and TG/.. Concentrations of g/l also had the lowest percent error with TG/.. When PG values were.1-. g/l, LDL cholesterol concentrations had the least error when TG/ was used. When they were >. gil, PG1 generally continued to give the smallest mean percent error, but with increasingly large standard deviations. Variability started to become noticeable when PG concentrations were >. gil, and when PG concentrations were.1-. g/l at least 1% of individuals had estimated LDL cholesterol concentrations that deviated from the measured values by >1%. At TG concentrations >. g/l this percentage increased to more than 7% of individuals (Table 1). As shown in Table and Figure 1, the potential for significant estimation errors increased steadily with the PG concentration. We then subdividedthe data (using NCEP criteria for total cholesterol and PG) to separately evaluate normolipidemics (cholesterol <., TG. gil, n = 9), hypercholesterolemics (cholesterol., TG. g/l, n = 9), moderate hypertriglyceridemics (cholesterol <., PG.1-. g/l, n = 17), and combined hyperlipidemics (cholesterol., PG.1-. g/l, n = ). In addition, a subset of the combined hyperlipidemics with VLDL cholesterol/pg ratios. (n = ) were analyzed separately as possible Type III hyperlipoproteinemics. Severe hypertriglyceridemics (n = 7) were not analyzed in these subgroups. The data are summarized in Table. The accuracy of estimation for the normolipidemics and the hypercholesterolemics was similar to that for the entire group shown in Table 1. The best estimating factor for the normolipidemics was TG/., with % having estimated UI I.- w ,1-1. TRLYCERIDE CONCENTRATION (gel) Fig. 1. Percent error for estimated LDL cholesterol associatedwith seven estimationfactors(tg/, TG/., TG/, TG/., TGI, TG/7, TGI) at varioustg ranges(gil) Each bar representsone standard deviationfromthe mean percent errorfor each factor. The dotted linerepresentsthe 1% cutpoint used for evaluating acceptable error.the #{19} shows the bar(s) in each TG rangewiththe smallest percent error LDL cholesterol values within 1% of the measured values. Normolipidemics, as defined here, represented 7% of our entire population. Hypercholesterolemics had an estimation accuracy rate of 91% with the factor PG/ and represented 19% of the population. Hypertriglyceridemics with PG.1-. gil were best estimated with factors TG/. and TG/, but only correctly estimated % of samples. The hypertriglyceridemics with PG >. gil were best estimated with the factor TG/; however, only 7% were correctly estimated within the 1% limits. Combined hyperlipidemics with PG values of.1-. gil were correctly estimated in 7% of cases using PG/.; for those with PG.1-. gil, % were correctly estimated with the factor TG/. The subgroup of combined hyperlipidem- ics, who, in addition to above-normal cholesterol and PG values, had VLDL cholesterolffg ratios., had a much lower rate of correct estimation, as would be expected. The number of those with PG of.1-. gil was small (n = 1), but they were best estimated with TG/, but at a rate of only 1%, and markedly lower rates for all other factors. Above PG of. gil, the number of individuals was equally small (n = 1), and none of the factors correctly estimated any of the samples. The entire group of combined Table. Mean (± SD) Percent Deviation of Estimated LDL Cholesterol from Measured LDL Cholesterola Factor used In estimation TO, g/l n TG/ TG/. TG/ TG/. TG/ TO/i TG/ 17*b 7b 7b 7b b. ± ± 1*b b #{7}gb ± ±9 7± #{7}*1 b ± ± 7± 9± *b b ± ± 9± 11± ±11 11*b ±1 7±11 11±11 1± ±1 -±1 #{7}*b ±1 9± 1±1 ± ± 1 - ± *b ± * ± ± 1 ± 1 ± ± ± *) 1 ± 7 ± 9 ± ± 9 7 ± ± - ± 7 - ± ± 1 ± 9 ± ± ± - ± 9 7 ± 7* ± 9 7 ± 7 97 ± 9 17 ± 1 >1. -1 ± ± 1 - ± -7 ± -1 ± 7 - ± 1 7 ± 1 a Within each TG range,* indicatesthe estimation factor withthe lowest percent error. b Estimation factors where the mean estimated LDL cholesterol and the meanmeasuredldl cholesterolconcentrationsvaried by.o g/l. CLINICAL CHEMISTRY, Vol., No. 1, 199

4 Table. Percent of Samples for Which LDL Cholesterol Was within 1% of Measured LDL Cholesterol, Grouped by Lipldemic Type Factor used In estimation Classif. TO, g/l. % Pop. 1/ 1/. TG/ TG/. TQ/ TO!? 1/ Normo. s. 7 * 7 Hyperchol. s HyperTGt. >. 1 7* Combinedcd s. >. 7* * 9 VLDLC/TG.. 1* c.d >.. aw,.j.ln each lipid category, * IndIcatesthe estimationfactorwith the greatest number of samples with less than 1% difference between measured and estimatedlolcholesterolconcentration.b Totalcholesterolconcentrations<. g/l. C Total cholesterol concentrations. g/ d1 concentrations between. and.g/l. hyperlipidemics with a VLDL cholesterolltg ratio. (potentially Type Ill individuals) represented only.% of our entire population, all of them coming from the HNRC population. The percentage of values classified correctly according to NCEP guidelines for estimated vs measured LDL cholesterol concentrations, utilizing all of the factors, are shown in Pables and, and Figure. Table provides the data for samples with PG s.o g/l and indicates that samples with the highest (1.9 g/l) and the lowest (<1. g/l) LDL cholesterol concentrations had the best rates of correct classification. This is due in part to misclassification errors in these ranges being unidirectional and in part to these categories containing more samples with concentrations that were farther from the decision levels of 1., 1., and 1.9 g/l. Samples with measured LDL cholesterol values in the middle ranges of 1. to 1.9 gil had the possibility of being misclassified bidirectionally. Pable B indicates that samples with measured LDL cholesterol concentrations differing by >.1 gil from a decision level were correctly classified -9% of the time, and that PG/. and PG/ were the two best estimation factors (9%). When mea- Table. Percent of Samples Properly Classified for LDL Cholesterol Content According to NCEP Guldellnes Classified by U/C Classified by estimation Estimation factors (% classified) g/l g/l n 1/ TG/. A) For TG. g/l <1. 9* 9 < o o i.9 1/ 1/. 1/ 117 1/ < i < i.9 i.9 o o * Overall < o * 79 7 B) For measuredldl cholesterol<.1 or.1 gil froma decisionlevel < * Overall 9* * 79 7 a WIthIneach NCEP category, * indicatestheestimationfactorwith the highestpercentofproperlyclassifiedsamples. In Tables and, the primary line In each groupingis in boldface, to simplifyunderstanding. U/C, ultracentrlfugation. CLINICAL CHEMISTRY, Vol., No. 1, 199 9

5 Classified by U/C Table. Percent of Samples Properly ClassIfiedfor LDL Cholesterol According to NCEP Guidelines, for TG >. g/la Classified by Estimation Estimation Factors (% classified) g/l g/l A) For TG,.1-. gil <1. < n 1/ 1/. 1/ 1/. 1/ * < * < * Overall < i * 1* B) For TG >. <1. < i * < i < i Overall < i a Within each NCEPcategory, * Indicatesthe estimationfactorwith the highest percent of properlyclassifiedsamples. U/C, ultracentrifugation sured concentrations were within.1 g/l of a decision level, however, samples were correctly classified in only -9% of cases, with TG/ having the highestrateat 9%. Data for samples with PG of.1-. g/l (Table A), and for samples with TG >. gil (Table SB) show similar distribution patterns. In all cases, regardless of PG concentrations, samples with the lowest measured LDL cholesterols were best classified with a low estimating factor (i.e., TG/) and, conversely, those with the highest measured values were best classified with a high factor (i.e., TG/). Of course, using TG/ causes one to estimate a lower LDL cholesterol and, conversely, using TG/ causes one to estimate a higher LDL cholesterol value for any given set of variables. Therefore, these latter findings are not surprising. Overall, PG/. was the best factor for PG values in the range.1-. g/l, and PG/ was the best classification factor when PG values were >. g/l. The number of samples in both of these groups was quite small, however, and the data were skewed, particularly in the lattergroup.properclassification into NCEP categories should not supercede the methods for most nearlyaccurate estimation, and our data indicate that at PG values >. g/l none of these methods allows for accurate estimates. At PG <. g/l, the factor PG/ provides a reasonable assessment of LDL cholesterol. CLINICALCHEMISTRY, Vol., No. 1, 199

6 Cl) >. -J (1) -j. C/) LL z 1 NCEP LDL CHOLESTEROL CUTPOINTS Fig.. Effect of estimatedldlcholesterolconcentrationson correct NCEP classificationfor each estimationfactor(tgi, TGI., TGI, TGI., TGI, TG/7, TG/) Open bars representsamples with TG c. gil; filled bars represent samples with TG.1-. gil Eachgroupof barsrepresentsone category of riskas definedby NCEP Discussion LDL cholesterol concentration has been recommended by the NCEP Adult Preatment Panel as the determining factor in initiating dietary and drug treatment (9), so it is important to understand the validity and limitations of reported values for LDL cholesterol. There is no method currentlyavailable for measuring LDL cholesterol directly from plasma or serum; thus this analyte must be measured after its separation by ultracentrifugation. Ultracentrifugation methodology was used by the Lipid Research Clinics in the Prevalence and Primary Prevention studies (,,1) and is generally regarded as the standard reference method. The ultracentrifugation technique depends on the accuracy of centrifugation, HDL precipitation, and the cholesterol assay. Owing to the expense and lack of availability of ultracentrifugation, however, methods were developed to estimate LDL cholesterol concentration. These estimation techniques must rely on the accuracy of the cholesterol and TG assays, the HDL precipitation, and also on an additional mathematical factor that is used in an attempt to estimate the VLDL cholesterol concentration. There has been some controversy as to the most nearly accurate estimation factor to use, and attempts have been made to evaluate and refine the original estimation calculations proposed by Friedewald et al. to decrease potential estimation errors (1, 1, 17-19). However, the most frequently used estimation method in clinical laboratories continues to be that of Friedewald et al. The present study was designed to re-evaluate the Friedewald and other estimation factors with regard to their impact on NCEP guidelines, and to examine the level of potential error associated with these mathematical estimation factors. We have previously confirmed that the Friedewald formula of TG/ is an appropriate factor for estimating VLDL and LDL cholesterol in individuals with PG. g/l (). Additionally, PGI also gave approximations of LDL cholesterol for individuals with elevated PG, but with a large margin of error (1). In the present study, we have re-examined those issues, using both normolipidemic and dyslipidemic adults (1-1 y), in conjunction with the examination of other calculation factors and NCEP adult classification guidelines. In addition, we have used automated enzymatic lipid assays of the type used in most clinical chemistry laboratories, including unblanked TG measurements, which differ from chemical methods used in our previous studies and in the Lipid Research Clinic studies. Because the identical values for total cholesterol, TG, and HDL cholesterol were used for both measuring and estimating each sample, and because these assays were CDC standardized, errors due to inaccuracy, imprecision, and biological variability were not assessed in this study. In clinical practice, however, variability must be minimized as much as possible with regard to assay reliability, duration of fasting before sampling (,), and interlaboratory standardization (). When comparing the estimated values with the measured values, we examined the data from two perspectives. The first analysis assessed how closely each estimated LDL cholesterol values approximated the measured value. For this we used a 1% deviation from the measured concentration as a cutpoint. This 1% range represented an allowable LDL cholesterol fluctuation of approximately.1 to. g/l (mean =. ±. gil; range =. to.9 g/l). Not surprisingly, the ability to correctly estimate LDL cholesterol concentration varied inversely with the PG concentration in the plasma. As seen in Table 1 and Figure 1, the proportion of samples falling within the fairly broad 1% range decreased continuously with increased PG concentration, irrespective of the calculation factor used. The standard deviation of the variation increased from ±7% for PG. gil, to ±1-1% at TG concentrations of.1-. g/l (Table ). Above. g/l, the standard deviation increased to ±% to more than ± 1% error. When we subdivided individuals according to their type of dyslipidemia (Table ), we found, as expected, that those with low PG concentrations (i.e., normolipidemics and hypercholesterolemics) usually were correctly estimated. Those with increased TG concentrations (i.e., hypertriglyceridemics and combined hyperlipidemics), however, were much less often correctly estimated, and the subgroup of combined hyperlipidemics with an abnormally high VLDL cholesterolffg ratio even more so. Fortunately, individuals in the latter subgroup are encountered infrequently in the general population-.% in our study-and their treatment would not differ substantially from that used for other combined hyperlipidemics. Unfortunately, these individuals are impossible to distinguish from other combined hyperlipidemics without ultracentrifugation and apolipoprotein E phenotyping. Because the NCEP Adult Treatment Panel guidelines are now being used as a basis for identifying and determining treatment of dyslipidemic individuals, our second assessment involved an examination of the accuracy of classification of LDL cholesterol values, derived through estimation, into various NCEP categories. Because the data used by NCEP for LDL cholesterol cutpoints were derived primarily from samples analyzed after ultracentrifugation, we believed it important to examine how individuals would be classified if ultracentrifugation were not available. Interestingly, as shown in Tables and and Figure, most individuals were properly classified, even though the esti- CLINICALCHEMISTRY, Vol., No. 1, 199 1

7 mated LDL cholesterol concentrations were less accurate than one would wish. Those with values farthest from a decision level (i.e., very low or very high values) were most accurately classified. Individuals with values close to the decision points, where accuracy is most critical, were naturally at the highest risk of misclassification (Table B). Because of this, it is particularly important that these individuals have their values rechecked to minimize inappropriate counseling. Additionally, it is extremely important that patients adhere to 1- to 1-h fasts, because those with higher PG concentrations are in double jeopardy of being misclassified: they (a) are subject to a higher rate of inaccurate LDL cholesterol estimation due to the elevation in PG and (b) are generally more sensitive to changes in plasma PG from dietary fat intake, often requiring a longer time to return to baseline after a meal (,). Our data clearly indicate the need for a convenient direct assay for measuring LDL cholesterol. However, at the present time, utilization of the original formula of Friedewald et al., with the factor TG/, appears to provide a reasonable alternative for individuals with PG <. g/l. For those with PG >. g/l, TG/ is still the factor that gives results most closely matching the measured LDL cholesterol, but the potential error is so great for any given individual that we do not recommend its use. It should be noted that the prevalence of LDL cholesterol values 1. g/l in subjects with TO >. gil is reasonably low (%, Table ). We recommend that these individuals (.% of our entire study; 1.% of the normal Framingham population) and those suspected of having Type ifi hyperlipoproteinemia be referred to specialized laboratories with facffities available for ultracentrifugal analysis if the type of lipsprotein abnormality is to be properly assessed (9). We thank Dr. Mary M. Schaefer (HNRC) for carrying out the statistical analysis, and Albina Mariano and Babe Bravo for performing all of the lipid and lipoprotein determinations for the FHS samples. This work was supported by GrantHL and Subcontract RFP NHLBI HV - from the National Heart, Lung and Blood Institute, and Contract -K--1O from the U.S. Dept. of Agriculture Research Service. References 1. Keys A, ed. Coronary heart study in seven countries. Circulation 197;1(Suppl):I Martin M,J, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 1, men. Lancet 19;ii:9-.. Castelli WP, Garrison RJ, Wilson PWF, Abbott RI), Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. J Am Med Assoc 19;:-.. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in the incidence of coronary heart disease. J Am Med Assoc 191:1-.. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: IL The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc 19;1:-7.. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 19;9:-. Elo, Haapa K, trial with with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 197;17: Frick MB, primary-prevention et al. Helsinki gemlibrozil in middle-aged Heart Study: men. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc 197;:-. 9. Expert Panel: Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 19;1: Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 19;: Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol without use of the preparative ultracentrifuge. in plasma, Cliii Chem 197;1: DeLongDM, DeLongER, Wood PD, Lippel K, Rilkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol: the Lipid Research Clinics Prevalence Study. J Am Med Asaoc 19;:7-7.. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acts 197;1: Warnick GR, Benderson J, Albers JJ. Dextran sulfate-mg precipitation procedure for quantitation of lipoprotein cholesterol. Clin Chem 19;:79-. high-density. 1. Kuba K, FrantzJr ID. Validity of the Friedewald equation for the estimation of plasma low-density lipoprotein cholesterol (LDL- C) at various concentrations of triglycerides [Abstract]. Clin Chem 197;:9. 1. The Lipid Research Clinics Program. Population Studies Data Book, vol. 1. The prevalence study. NIH publ. no Washington, DC: US Govt Printing Office, NiedbalaRS, Schray KJ, Foery R, Clement G. Estimation of low-density lipoprotein by the Friedewsid formula and by electrophoresis compared [Letter]. Cliii Chem 19;1: Lippi U, Graziani ME, Manzato F, Schinella M. The Friedewald formuim statistical acrobatics? [Letter]. Clin Chem 19;: Rao A, Parker All, El-Sheroni NA, Babelly MM. Calculation of low-density lipoprot.ein cholesterol with use of triglyceride/ cholesterol ratios in lipoproteins compared with other calculation methods. Clin Chem 19;:-.. Wilson PW, Abbott RI), Garrison RJ, Castelli WP. Estimation of very-low-density lipoprotein cholesterol from data on triglyceride concentration in plasma. Cliii Chem 1917: Wilson PWF, Zech LA, Gregg RE, et al. Estimation of VLDL cholesterol in hyperlipidemia.clin Chin Acts 19;11:-91.. CohnJS, McNamara JR, Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjectsasmeasured in the fed and fasted states. Cliii Chem 19;:-9.. CohnJS, McNamara JR. Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoproteinchanges in human subjects of different ages. J Lipid Rae 19;:9-.. Current status of blood cholesterol measurement in clinical laboratories in the United States: a report from the Laboratory Standardization Panel of the NationalCholesterol Education Program. Clin Chem 19;:19-1. CLINICALCHEMISTRY,Vol., No. 1, 199

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee

Katsuyuki Nakajima, PhD. Member of JCCLS International Committee Katsuyuki Nakajima, PhD Member of JCCLS International Committee Visiting Professor and Scientist Tufts University, Boston, MA & Framingham Offspring Study, Framingham, MA August 20 th, 2011, Tokyo Framingham

More information

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients

ARTICLE. Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients ARTICLE Utility of Direct Measurement of Low-Density Lipoprotein Cholesterol in Dyslipidemic Pediatric Patients Baruch S. Ticho, MD, PhD; Ellis J. Neufeld, MD, PhD; Jane W. Newburger, MD, MPH; Neil Harris,

More information

Comparison of two assays for measuring LDL cholesterol

Comparison of two assays for measuring LDL cholesterol Clinical Chemistry 43:6 1040 1047 (1997) Lipids and Lipoproteins Comparison of two assays for measuring LDL cholesterol Anirban Maitra, Shaina V. Hirany, and Ishwarlal Jialal* The purpose of this study

More information

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India

The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,

More information

Evaluation of Calculated Low-Density Lipoprotein Against a Direct Assay

Evaluation of Calculated Low-Density Lipoprotein Against a Direct Assay Evaluation of Calculated Low-Density Lipoprotein Against a Direct Assay Navapun Charuruks MD*, Anna Milintagas BSc** * Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University **

More information

When Do We Treat Hypercholesterolemia?

When Do We Treat Hypercholesterolemia? Clin. Cardiol. 15 (Suppl. In>, 111-10-111-14 (1992) When Do We Treat Hypercholesterolemia? w. VIRGIL BROWN, M.D. Department of Medicine, Emory University, Atlanta, Georgia, USA Summary: Although the relationships

More information

Lipid Profile Analysis of Aircrew

Lipid Profile Analysis of Aircrew Original Article Lipid Profile Analysis of Aircrew Sampath S *, Richa + ABSTRACT Most laboratories including all our Armed Forces Centers, estimate Low Density Lipoproteins Cholestorol (LDL-C) levels with

More information

LDL . (LDL) Downloaded from ijdld.tums.ac.ir at 12:38 IRST on Friday February 1st 2019 LDL LDL NCEP-ATP-III (LDL) :

LDL . (LDL) Downloaded from ijdld.tums.ac.ir at 12:38 IRST on Friday February 1st 2019 LDL LDL NCEP-ATP-III (LDL) : 197-207 (2 ) 10 1389 -. 2 1 1* :.. 352 :... (TG). (). -.(r= 0/95) :. TG. NCEP-ATP-III. :. () : -1-2 1593748711 : ronakn2000@yahoo.com : 88942661-5 09124135284 ... : 198.[4]. 1990 -. C.[4]. NCEP.[4]...

More information

Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia

Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,

More information

COMPARISON OF CALCULATED AND DIRECT LOW DENSITY LIPOPROTEIN CHOLESTEROL DETERMINATIONS IN A ROUTINE LABORATORY. A. A. AMAYO and S.

COMPARISON OF CALCULATED AND DIRECT LOW DENSITY LIPOPROTEIN CHOLESTEROL DETERMINATIONS IN A ROUTINE LABORATORY. A. A. AMAYO and S. 154 EAST AFRICAN MEDICAL JOURNAL March 2004 East African Medical Journal Vol. 81 No. 3 March 2004 COMPARISON OF CALCULATED AND DIRECT LOW DENSITY LIPOPROTEIN CHOLESTEROL DETERMINATIONS IN A ROUTINE LABORATORY

More information

The Second Report of the Expert Panel on Detection,

The Second Report of the Expert Panel on Detection, Blood Cholesterol Screening Influence of State on Cholesterol Results and Management Decisions Steven R. Craig, MD, Rupal V. Amin, MD, Daniel W. Russell, PhD, Norman F. Paradise, PhD OBJECTIVE: To compare

More information

Patricia C. Fallest-Strobl, 1 Elin Olafsdottir, 2 Donald A. Wiebe, 1 and James O. Westgard 1 * Lipoproteins

Patricia C. Fallest-Strobl, 1 Elin Olafsdottir, 2 Donald A. Wiebe, 1 and James O. Westgard 1 * Lipoproteins Clinical Chemistry 43:11 2164 2168 (1997) Lipids and Lipoproteins Comparison of NCEP performance specifications for triglycerides, HDL-, and LDL-cholesterol with operating specifications based on NCEP

More information

Separation of HDL Particles by Immunoprecipitation

Separation of HDL Particles by Immunoprecipitation Sun Diagnostics, LLC Separation of HDL Particles by Immunoprecipitation Rae-Anne Nguyen and John H. Contois 13 Introduction We all know that HDL cholesterol concentration is inversely associated with coronary

More information

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,

More information

Friedewald formula. ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5. Friedewald formula. Friedewald formula

Friedewald formula. ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5. Friedewald formula. Friedewald formula Friedewald formula 1 1 1,2 ATP Adult Treatment Panel III L D L Friedewald formula L D L = T- C H O - H D L - T G / 5 Friedewald formula Friedewald formula 2003 99 Friedewald formula Colorimetric method

More information

Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population

Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population Applicability of Cholesterol-Lowering Primary Prevention Trials to a General Population The Framingham Heart Study ORIGINAL INVESTIGATION Donald M. Lloyd-Jones, MD; Christopher J. O Donnell, MD, MPH; Ralph

More information

Comparison of a Homogeneous Assay With a Precipitation Method for the Measurement of HDL Cholesterol in Diabetic Patients

Comparison of a Homogeneous Assay With a Precipitation Method for the Measurement of HDL Cholesterol in Diabetic Patients Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Comparison of a Homogeneous Assay With a Precipitation Method for the Measurement of HDL Cholesterol in Diabetic Patients TONNY JENSEN, MD

More information

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C

More information

Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients

Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients Clinical Biochemistry 34 (2001) 593 602 Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients Eleni Bairaktari a, *, Moses Elisaf b, Christos Tzallas

More information

Coverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests

Coverage Guidelines. NMR LipoProfile and NMR LipoProfile -II Tests Coverage Guidelines NMR LipoProfile and NMR LipoProfile -II Tests Disclaimer: Please note that Baptist Health Plan updates Coverage Guidelines throughout the year. A printed version may not be most up

More information

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required

More information

EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS. Kamsiah Jaarin, Nafeeza MI*

EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS. Kamsiah Jaarin, Nafeeza MI* REVIEW ARTICLE Malaysian Journal of Medical Sciences, Vol. 6, No. 2, July 1999 (5-11) EFFECT OF NICARDIPINE ON FASTING PLASMA LIPIDS AND APOLIPOPROTEINS IN MALE NEW ZEALAND WHITE RABBITS Kamsiah Jaarin,

More information

Epidemiology of Blood Lipids and Lipoproteins

Epidemiology of Blood Lipids and Lipoproteins Epidemiology of Blood Lipids and Lipoproteins 2 Peter W.F. Wilson Introduction Research has shown that total cholesterol levels in the blood are highly associated with greater coronary heart disease (CHD)

More information

Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?

Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come? Papers in Press. Published January 19, 2016 as doi:10.1373/clinchem.2015.247866 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.247866 Clinical Chemistry 62:3 000 000

More information

Cholesterol Screening: Comparative Evaluation of On-Site and Laboratory-Based Measurements

Cholesterol Screening: Comparative Evaluation of On-Site and Laboratory-Based Measurements CLIN. CHEM. 36/2, 255-260 (1990) Cholesterol Screening: Comparative Evaluation of On-Site and Laboratory-Based Measurements Paul S. Bachorlk,1 Robert Rock,2 Teresa Cloey,1 Ester Treciak,2 Diane Becker,3

More information

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV

LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 4 (53) No. 2-2011 LIPIDS AND CHOLESTEROL - RISK FACTORS TO A POLICE UNIT FROM BRASOV C. DOBRESCU 1 I. MOLEAVIN 1 Abstract:

More information

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI

Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Walter B. Bayubay CLS (ASCP), AMT, MA Ed, CPI Biochemical Analysis (Lipid Panel) Analyte Total Cholesterol Reference Range Patient A < 200 241 LDL-C /= 40 38 Triglycerides

More information

Screening for Total Cholesterol

Screening for Total Cholesterol 1287 Screening for Total Cholesterol Do the National Cholesterol Education Program's Recommendations Detect Individuals at High Risk of Coronary Heart Disease? Trudy L. Bush, PhD, MHS, and Denise Riedel,

More information

Investigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats

Investigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats J. Biosci., Vol. 12, Number 2, June 1987, pp. 137 142. Printed in India. Investigations on the mechanism of hypercholesterolemia observed in copper deficiency in rats P. VALSALA and P. A. KURUP Department

More information

ORIGINAL INVESTIGATION. The Lipid Treatment Assessment Project (L-TAP)

ORIGINAL INVESTIGATION. The Lipid Treatment Assessment Project (L-TAP) ORIGINAL INVESTIGATION The Lipid Treatment Assessment Project (L-TAP) A Multicenter Survey to Evaluate the Percentages of Dyslipidemic Patients Receiving Lipid-Lowering Therapy and Achieving Low-Density

More information

Diet and Cholesterol Guidelines and Coronary Heart Disease*

Diet and Cholesterol Guidelines and Coronary Heart Disease* JACC Vol. 13, No. 2 February 1989:503-7 503 Diet and Cholesterol Guidelines and Coronary Heart Disease* ANTONIO M. GOTTO, JR., MD, DPHIL Houston, Texas It is important to have public debate on critical

More information

Martin/Hopkins Estimation, Friedewald and Beta- Quantification of LDL-C in Patients in FOURIER

Martin/Hopkins Estimation, Friedewald and Beta- Quantification of LDL-C in Patients in FOURIER TAP TO GO BACK TO KIOSK MENU Seth S. Martin, M.D., M.H.S., Robert P. Giugliano, M.D., S.M., 2 Sabina A. Murphy, M.P.H., 2 Scott M. Wasserman, M.D., 3 Peter S. Background Evolocumab, a fully human monoclonal

More information

High Density Lipoprotein Cholesterol and Mortality

High Density Lipoprotein Cholesterol and Mortality High Density Lipoprotein Cholesterol and Mortality The Framingham Heart Study Peter W.F. Wilson, Robert D. Abbott, and William P. Castelli In 12 years of follow-up for 2748 Framingham Heart Study participants

More information

Cardiovascular Disease

Cardiovascular Disease 8 High-Density Lipoprotein Cholesterol and Cardiovascular Disease Four Prospective American Studies David J. Gordon, MD, PhD, Jeffrey L. Probstfield, MD, Robert J. Garrison, MS, James D. Neaton, PhD, William

More information

Human Nutrition and Metabolism

Human Nutrition and Metabolism Human Nutrition and Metabolism Fish Consumption Shifts Lipoprotein Subfractions to a Less Atherogenic Pattern in Humans 1 Zhengling Li, Stefania Lamon-Fava, James Otvos,* Alice H. Lichtenstein, Wanda Velez-Carrasco,

More information

Postprandial plasma lipoprotein changes in human subjects of different ages

Postprandial plasma lipoprotein changes in human subjects of different ages Postprandial plasma lipoprotein changes in human subjects of different ages Jeffrey S. Cohn, Judith R. McNamara, Susan D. Cohn, Jose M. Ordovas, and Ernst J. Schaefer Lipid Metabolism Laboratory, USDA

More information

Medication compliance and serum lipid changes in the Helsinki

Medication compliance and serum lipid changes in the Helsinki Br. J. clin. Pharmac. (1991), 32, 409415 Medication compliance and serum lipid changes in the Helsinki Heart Study HANNA MAENPAA, 0. P. HEINONEN & V. MANNINEN First Department of Medicine, University of

More information

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

Accuracy of Three Dry-Chemistry Methods for Lipid Profiling and Risk Factor Classification

Accuracy of Three Dry-Chemistry Methods for Lipid Profiling and Risk Factor Classification 358 International / Rubin Journal et al. of Sport Nutrition and Exercise Metabolism, 2003, 13, 358-368 2003 Human Kinetics Publishers, Inc. Accuracy of Three Dry-Chemistry Methods for Lipid Profiling and

More information

Depleting Lipoproteins from Serum

Depleting Lipoproteins from Serum Depleting Lipoproteins from Serum Kathy K. Foxx Kalen Biomedical LLC President For decades, fetal bovine serum (FBS) has been used as a supplement for cell-culture media, providing the growth factors that

More information

Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases

Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Original article: Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Dr Abhijit Nikam, Dr Sonu Yadav, Dr Vivek Chiddarwar, Dr A L Kakrani Dept of Medicine,

More information

Effects of Age, Sex, and Menopausal Status on Blood Cholesterol Profile in the Korean Population

Effects of Age, Sex, and Menopausal Status on Blood Cholesterol Profile in the Korean Population Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Effects of, Sex, and Menopausal Status on Blood Cholesterol Profile in the Korean Population Ji Hye Park, BS 1, Myung

More information

Heart Disease: Old or New?

Heart Disease: Old or New? Heart Disease: Old or New? David Sullivan, Dept Biochemistry RPAH David.Sullivan@sswahs.nsw.gov.au A historical timeline for atherothrombotic cardiovascular disease The past present future continuum for

More information

Dr. Kulkarni addressing members at the meeting. topics in cardiovascular diseases are traditionally

Dr. Kulkarni addressing members at the meeting. topics in cardiovascular diseases are traditionally Volume 1 Issue 1 Fall, 2015 INSIDE THIS ISSUE: Chair s Corner 1 Editorial 2 LDL-C < 70 mg/dl 3 Journal Watch 7 Division Officers Krishnaji R. Kulkarni, Chair Amar A. Sethi, Chair-Elect Sridevi Devaraj,

More information

Laboratory Investigation of Dyslipidemia

Laboratory Investigation of Dyslipidemia CHEMISTRY Sridevi Devaraj, PhD Ishwarlal Jialal, MD, PhD, FRCPath, DABCC Laboratory Investigation of Dyslipidemia Cardiovascular disease is the leading cause of lesterol nor triglycerides are soluble in

More information

Lipoprotein (a): Is it important for Friedewald formula?

Lipoprotein (a): Is it important for Friedewald formula? ORIGINAL RESEARCH ALBANIAN MEDICAL JOURNAL Lipoprotein (a): Is it important for Friedewald formula? Murat Can 1, Berrak Guven 1 1 Bulent Ecevit University, Faculty of Medicine, Department of Biochemistry

More information

Serum low-density lipoprotein and high-density lipoprotein cholesterol. determined by ultracentrifugation and high-performance liquid

Serum low-density lipoprotein and high-density lipoprotein cholesterol. determined by ultracentrifugation and high-performance liquid Serum low-density lipoprotein and high-density lipoprotein cholesterol determined by ultracentrifugation and high-performance liquid chromatography Jun Dong, 1 Hanbang Guo, 1 Ruiyue Yang, 1 Hongxia Li,

More information

LIPOPROTEIN PROFILING

LIPOPROTEIN PROFILING LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known

More information

Elevated serum triglyceride concentrations

Elevated serum triglyceride concentrations Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Elevated Remnant-Like Particle Cholesterol and Triglyceride Levels in Diabetic Men and Women in the Framingham Offspring

More information

Macrovascular Management. What s next beyond standard treatment?

Macrovascular Management. What s next beyond standard treatment? Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk

More information

Ingmar Jungner, 1* Santica M. Marcovina, 2 Göran Walldius, 3 Ingar Holme, 4 Werner Kolar, 1 and Eugen Steiner 1. Lipoproteins

Ingmar Jungner, 1* Santica M. Marcovina, 2 Göran Walldius, 3 Ingar Holme, 4 Werner Kolar, 1 and Eugen Steiner 1. Lipoproteins Clinical Chemistry 44:8 1641 1649 (1998) Lipids and Lipoproteins Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization International

More information

Low Density Lipoprotein Particle Size and Coronary Artery Disease

Low Density Lipoprotein Particle Size and Coronary Artery Disease 187 Low Density Lipoprotein Particle Size and Coronary Artery Disease Hannia Campos, Jacques J. Genest Jr., Erling Blijlevens, Judith R. McNamara, Jennifer L. Jenner, Jos6 M. Ordovas, Peter W.F. Wilson,

More information

Lipid Profiles. Important: Read over the section on correlation coefficients in the Guidelines for Statistics and Graphs in General Education Biology.

Lipid Profiles. Important: Read over the section on correlation coefficients in the Guidelines for Statistics and Graphs in General Education Biology. Biology 104 Lipid Profiles Important: Read over the section on correlation coefficients in the Guidelines for Statistics and Graphs in General Education Biology. Objectives: 1. Learn about the different

More information

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32. Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043

More information

Association of Plasma Lipid profile and HbA1c among Saudi Patients with Coronary Heart Diseases, at King Abdulaziz Medical City, Riyadh

Association of Plasma Lipid profile and HbA1c among Saudi Patients with Coronary Heart Diseases, at King Abdulaziz Medical City, Riyadh EUROPEAN ACADEMIC RESEARCH Vol. III, Issue 10/ January 2016 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Association of Plasma Lipid profile and HbA1c among Saudi

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

Paul S. Bachorik,' Robert E. Walker, and Peter 0. Kwiterovich, Jr.

Paul S. Bachorik,' Robert E. Walker, and Peter 0. Kwiterovich, Jr. papers and notes on methodology Determination of high density lipoprotein-cholesterol in human plasma stored at -7OOC Paul S. Bachorik,' Robert E. Walker, and Peter 0. Kwiterovich, Jr. Departments of Pediatrics

More information

Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips

Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips Accuracy and Precision in Point-of-Care Lipid Testing: CardioChek P A Point-of-Care Test System and PTS Panels Test Strips Sponsored by Arthur Roberts, MD of The Living Heart Foundation The Living Heart

More information

Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk

Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk Pacific University CommonKnowledge School of Physician Assistant Studies Theses, Dissertations and Capstone Projects Summer 8-13-2016 Nonfasting LDL-C as a Predictor of Cardiovascular Event Risk Richard

More information

New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol

New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol Clinical Chemistry 44:7 1443 1451 (1998) Lipids and Lipoproteins New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol

More information

Categories of abnormal glucose homeostasis

Categories of abnormal glucose homeostasis Impaired Glucose Tolerance, but not Impaired Fasting Glucose, Is Associated With Increased Levels of Coronary Heart Disease Risk Factors Results From the Baltimore Longitudinal Study on Aging Deirdre R.

More information

Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial

Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial European Heart Journal (2003) 24, 1843 1847 ARTICLE IN PRESS Clinical research Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo

More information

Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease

Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease 2025 Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease Jacques J. Genest Jr., MD; Sarah S. Martin-Munley, PhD; Judith R. McNamara, MT; Jose M. Ordovas, PhD; Jennifer Jenner,

More information

ASSESMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL BY HOMOGENEOUS ASSAY VERSUS FRIEDEWALD S EQUATION - A STUDY OF 50 CASES.

ASSESMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL BY HOMOGENEOUS ASSAY VERSUS FRIEDEWALD S EQUATION - A STUDY OF 50 CASES. Volume: I: Issue-1 May-July -2010 ASSESMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL BY HOMOGENEOUS ASSAY VERSUS FRIEDEWALD S EQUATION - A STUDY OF 50 CASES. Lincy Jacob 1, Ravikanth Medikonda 2, Piyush

More information

Factors Associated with Lipoprotein Cholesterol Levels

Factors Associated with Lipoprotein Cholesterol Levels Factors Associated with Lipoprotein Cholesterol Levels The Framingham Study Peter W. F. Wilson, Robert J. Garrison, Robert D. Abbott, and William P. Castelli Lipoprotein cholesterol determinations in 6328

More information

PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL

PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL Lipids are characterized by low polarity and limited solubility in water. Their plasma concentration is about 500-600

More information

Electrolyte Analyzer with Ion-Selective Electrode and Blood Gas analyzer

Electrolyte Analyzer with Ion-Selective Electrode and Blood Gas analyzer Biochemistry & Fundamental Reference Laboratory, Yokohama Our Head Office and Biochemistry Reference Laboratory moved to Yokohama with aims to have further development on the 21 st September, 2018. [Reference

More information

10. HYPERLIPIDEMIA. Beatrice Golomb, MD, PhD

10. HYPERLIPIDEMIA. Beatrice Golomb, MD, PhD 10. HYPERLIPIDEMIA Beatrice Golomb, MD, PhD The development of quality indicators for screening and treatment of hyperlipidemia was initially based on current guidelines and review articles on hyperlipidemia.

More information

Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides

Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides Fredrik Karpe, 1, *, Susanna Boquist,* Rong Tang, Gene M. Bond,

More information

Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels

Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,

More information

HDL CHOLESTEROL. 01 English - Ref.: 13. Ref.:13. Insert

HDL CHOLESTEROL. 01 English - Ref.: 13. Ref.:13. Insert HDL CHOLESTEROL Insert Ref.:13 Intended use. System for selective precipitation of Low and Very Low Density Lipoproteins (LDL and VLDL) and HDL cholesterol measurement in the supernatant, by an end point

More information

Calibration of High-Density Lipoprotein Cholesterol Values From the Korea National Health and Nutrition Examination Survey Data, 2008 to 2015

Calibration of High-Density Lipoprotein Cholesterol Values From the Korea National Health and Nutrition Examination Survey Data, 2008 to 2015 Original Article Clinical Chemistry Ann Lab Med 217;37:1-8 https://doi.org/1.3343/alm.217.37.1.1 ISSN 2234-386 eissn 2234-3814 Calibration of High-Density Lipoprotein Cholesterol Values From the Korea

More information

LDL Particle Size Distribution. Results From the Framingham Offspring Study

LDL Particle Size Distribution. Results From the Framingham Offspring Study 1410 LDL Particle Size Distribution Results From the Framingham Offspring Study Hannia Campos, Erling Blijlevens, Judith R. McNamara, Jose" M. Ordovas, Barbara M. Posner, Peter W.F. Wilson, William P.

More information

ORIGINAL ARTICLE INTRODUCTION. Jongseok Lee 1, Sungok Jang 2, Haemin Jeong 3, and Ohk-Hyun Ryu 3

ORIGINAL ARTICLE INTRODUCTION. Jongseok Lee 1, Sungok Jang 2, Haemin Jeong 3, and Ohk-Hyun Ryu 3 ORIGINAL ARTICLE 2018 Mar 21. [Epub ahead of print] https://doi.org/10.3904/kjim.2017.233 Validation of the Friedewald formula for estimating low density lipoprotein cholesterol: the Korea National Health

More information

John J. Albers and Janet L. Adolphson

John J. Albers and Janet L. Adolphson Comparison of commercial kits for apoprotein A-I and apoprotein B with standardized apoprotein A-I and B radioimmunoassays performed at the Northwest Lipid Research Center John J. Albers and Janet L. Adolphson

More information

Shinichi Usui, 1 Masakazu Nakamura, 2 Kazuhiro Jitsukata, 3 Masayuki Nara, 4 Seijin Hosaki, 1 and Mitsuyo Okazaki 4*

Shinichi Usui, 1 Masakazu Nakamura, 2 Kazuhiro Jitsukata, 3 Masayuki Nara, 4 Seijin Hosaki, 1 and Mitsuyo Okazaki 4* Clinical Chemistry 46:1 63 72 (2000) Lipids, Lipoproteins, and Cardiovascular Risk Factors Assessment of Between-Instrument Variations in a HPLC Method for Serum Lipoproteins and Its Traceability to Reference

More information

Triglyceride determination

Triglyceride determination Triglyceride determination Introduction: - Triglycerides are esters of fatty acids and are hydrolyzed to glycerol and free fatty acids (by lipase) - Triglyceride determinations when performed in conjunction

More information

Evaluation of a Rapid Homogeneous Method for Direct Measurement of High-Density Lipoprotein Cholesterol

Evaluation of a Rapid Homogeneous Method for Direct Measurement of High-Density Lipoprotein Cholesterol Clinical Chemistry / ORIGINAL ARTICLE Evaluation of a Rapid Homogeneous Method for Direct Measurement of High-Density Lipoprotein Cholesterol R. Scott Hubbard, MD,1 Shaina V. Hirany, MS,2 Sridevi Devaraj,

More information

Clinical Investigation and Reports

Clinical Investigation and Reports Clinical Investigation and Reports Effect of 7-Year Infancy-Onset Dietary on Serum Lipoproteins and Lipoprotein Subclasses in Healthy Children in the Prospective, Randomized Special Turku coronary Risk

More information

The New England Journal of Medicine

The New England Journal of Medicine EFFECTS OF DIET AND EXERCISE IN MEN AND POSTMENOPAUSAL WOMEN WITH LOW LEVELS OF HDL CHOLESTEROL AND HIGH LEVELS OF LDL CHOLESTEROL MARCIA L. STEFANICK, PH.D., SALLY MACKEY, M.S., R.D., MARY SHEEHAN, M.S.,

More information

Keywords: Type 2 DM, lipid profile, metformin, glimepiride ABSTRACT

Keywords: Type 2 DM, lipid profile, metformin, glimepiride ABSTRACT Human Journals Research Article September 2015 Vol.:4, Issue:2 All rights are reserved by K. Saravanan et al. Effects of Monotherapy and Combination Therapy Involving Metformin and Glimepiride on HbA1c

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 340 J UNE 24, 1999 NUMBER 25 EFFECTS OF DIFFERENT FORMS OF DIETARY HYDROGENATED FATS ON SERUM LIPOPROTEIN

More information

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD ) 005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,

More information

HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart

HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT

More information

50 Facts on Statins, Cholesterol and Heart Health

50 Facts on Statins, Cholesterol and Heart Health 50 Facts on Statins, Cholesterol and Heart Health Written and Contributed by Site Member Pat Dougan 1. Vitamin D is synthesized from cholesterol by sunlight. 2. Cholesterol is the precursor for a whole

More information

The effect of cholesterol-related knowledge on patients' ability to reach target cholesterol levels

The effect of cholesterol-related knowledge on patients' ability to reach target cholesterol levels Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2003 The effect of cholesterol-related knowledge on patients' ability

More information

The Best Lipid Fraction for the Prediction of the Population at Risk of Atherothrombotic Disease. William E. Feeman, Jr., M.D.

The Best Lipid Fraction for the Prediction of the Population at Risk of Atherothrombotic Disease. William E. Feeman, Jr., M.D. The Best Lipid Fraction for the Prediction of the Population at Risk of Atherothrombotic Disease William E. Feeman, Jr., M.D. 640 South Wintergarden Road Bowling Green, Ohio 43402 Phone 419-352-4665 Fax

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

Research Article Anti hyperlipidemic Activity of Costus Igneus in Triton X- 100 Induced Hyperlipidemic Rats

Research Article Anti hyperlipidemic Activity of Costus Igneus in Triton X- 100 Induced Hyperlipidemic Rats Research Article Anti hyperlipidemic Activity of Costus Igneus in Triton X- 100 Induced Hyperlipidemic Rats Nimmy Chacko*, Shastry CS, Prerana shetty, Prasanna Shyamma, Ullas D souza and Patel Maulika

More information

Serum LDL- and HDL-cholesterol determined by ultracentrifugation and HPLC

Serum LDL- and HDL-cholesterol determined by ultracentrifugation and HPLC Serum LDL- and HDL-cholesterol determined by ultracentrifugation and HPLC methods Jun Dong, * Hanbang Guo, * Ruiyue Yang, * Hongxia Li, * Shu Wang, * Jiangtao Zhang, and Wenxiang Chen 1, *, Institute of

More information

Current Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations

Current Challenges in CardioMetabolic Testing. Kenneth French, Director of Clinical Operations Current Challenges in CardioMetabolic Testing Kenneth French, Director of Clinical Operations Disclosers Employee at VAP Diagnostics Laboratory Outline Cardiometabolic Disease: Current Challenges and Methodology

More information

HDL Purification Kit (Ultracentrifugation Free)

HDL Purification Kit (Ultracentrifugation Free) Product Manual HDL Purification Kit (Ultracentrifugation Free) Catalog Number STA- 607 10 preps FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Lipoproteins are submicroscopic particles

More information

Application of New Cholesterol Guidelines to a Population-Based Sample

Application of New Cholesterol Guidelines to a Population-Based Sample The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,

More information

Comparison of Different estimated Formulas with Direct Estimation of Low-density Lipoprotein Cholesterol

Comparison of Different estimated Formulas with Direct Estimation of Low-density Lipoprotein Cholesterol IJMB Comparison of Different estimated Formulas with Direct Estimation of 10.5005/jp-journals-10054-0040 Low-density Lipoprotein Cholesterol RESEARCH ARTICLE Comparison of Different estimated Formulas

More information

Comparison of various formulae for estimating low-density lipoprotein cholesterol by a combination of ages and genders in Taiwanese adults

Comparison of various formulae for estimating low-density lipoprotein cholesterol by a combination of ages and genders in Taiwanese adults Tsai et al. BMC Cardiovascular Disorders 2014, 14:113 RESEARCH ARTICLE Open Access Comparison of various formulae for estimating low-density lipoprotein cholesterol by a combination of ages and genders

More information

Application of New Cholesterol Guidelines to a Population-Based Sample

Application of New Cholesterol Guidelines to a Population-Based Sample The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Correlation of Serum Lipids and Lipoproteins with Trace Elements in Water Buffalo (Bubalus bubalis)

Correlation of Serum Lipids and Lipoproteins with Trace Elements in Water Buffalo (Bubalus bubalis) Veterinary Research Forum Vol: 1, No: 2, September, 2010, 91-97 Correlation of Serum Lipids and Lipoproteins with Trace Elements in Water Buffalo (Bubalus bubalis) Javad Tajik 1 * Saeed Nazifi 1 1 Department

More information